American Society of Addiction Medicine
American Society of Addiction Medicine
Lead: Overdose mortality incidence and supervised consumption services
Lead: Overdose mortality incidence and supervised consumption services
Lead: Overdose mortality incidence and supervised consumption services
Tuesday 20th February 2024
Explore the impact of supervised consumption sites on overdose deaths and other key studies in addiction medicine with Claire Rasmussen.
6 minutes
Informative
Compassionate
Supportive
Educational
Engaging
About this podcast
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Nutritional Pathways to Recovery
Navigating Intimate Relationships
Links:
Visit site
Episodes:
140 (View all)
Do you want to link to this podcast?
Get the buttons here!Life-Saving Insights: Supervised Consumption Sites & Addiction Trends
Episode Overview
- Supervised consumption sites significantly reduce overdose deaths.
- Psilocybin seizures indicate rising non-medical use.
- No difference found between 4mg and 8mg naloxone doses.
- Buprenorphine access needs expansion, especially for those with co-occurring conditions.
- State alcohol policies impact infant health.
In the 15 neighbourhoods within 500 meters of an SCS, overdose deaths decreased by 67%
Dive into this episode of 'This Week in Addiction Medicine' as host Claire Rasmussen sheds light on some groundbreaking studies and their impact on addiction treatment and policies. The lead story focuses on the significant reduction in overdose deaths in Toronto following the implementation of nine supervised consumption sites (SCS) between 2017 and 2019. With a 67% decrease in overdose deaths in neighbourhoods within 500 meters of these sites, the findings highlight the life-saving potential of SCS.
The episode doesn't stop there. You'll also hear about a fascinating study on the rise of psilocybin seizures in the United States, indicating an increase in non-medical use. Another study evaluates the effectiveness of different naloxone doses administered by law enforcement during opioid overdose responses, revealing no significant difference in outcomes between 4mg and 8mg doses. The Veterans Health Administration's initiative to expand access to buprenorphine in primary care settings is also discussed.
This study underscores the need for broader access and targeted interventions, especially for those with co-occurring mental health conditions. Additionally, there's a thought-provoking piece on opioid-induced hypogonadism and its implications for treatment retention. Finally, the episode touches on the importance of prevention and support for families affected by the opioid epidemic, as well as the impact of state alcohol policies on infant health.
With a mix of compelling data and real-world implications, this episode offers valuable insights for anyone interested in addiction medicine. If you're keen to understand the latest developments in addiction treatment and policy, this episode is a must-listen. How do you think supervised consumption sites could change the landscape of addiction treatment in your area?